Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Myocardial and Microvascular Injury in Acute Myocardial Infarction: Insights From the Randomized MonAMI Trial

Thomas Stiermaier, Philipp Schaefer, Roza Meyer-Saraei, Mohammed Saad, Suzanne de Waha-Thiele, Janine Pöss, Georg Fuernau, Tobias Graf, Thomas Kurz, Alex Frydrychowicz, Jörg Barkhausen, Steffen Desch, Holger Thiele, Ingo Eitel, Thomas Stiermaier, Philipp Schaefer, Roza Meyer-Saraei, Mohammed Saad, Suzanne de Waha-Thiele, Janine Pöss, Georg Fuernau, Tobias Graf, Thomas Kurz, Alex Frydrychowicz, Jörg Barkhausen, Steffen Desch, Holger Thiele, Ingo Eitel

Abstract

Background Intravenous morphine administration can adversely affect platelet inhibition induced by P2Y12 receptor inhibitors after acute myocardial infarction. In contrast, some evidence suggests that opioid agonists may have cardioprotective effects on the myocardium. The aim of this prospective, randomized MonAMI (Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Platelet Inhibition in Acute Myocardial Infarction) trial was, therefore, to investigate the impact of morphine with or without metoclopramide coadministration on myocardial and microvascular injury. Methods and Results Patients with acute myocardial infarction (n=138) were assigned in a 1:1:1 ratio to ticagrelor 180 mg plus: (1) intravenous morphine 5 mg (morphine group); (2) intravenous morphine 5 mg and metoclopramide 10 mg (morphine+metoclopramide group); or (3) intravenous placebo (control group) administered before primary percutaneous coronary intervention. Cardiac magnetic resonance imaging was performed in 104 patients on day 1 to 4 after the index event. Infarct size was significantly smaller in the morphine only group as compared with controls (percentage of left ventricular mass, 15.5 versus 17.9; P=0.047). Furthermore, the number of patients with microvascular obstruction was significantly lower after morphine administration (28% versus 54%; P=0.022) and the extent of microvascular obstruction was smaller (percentage of left ventricular mass, 0 versus 0.74; P=0.037). In multivariable regression analysis, morphine administration was independently associated with a reduced risk for the occurrence of microvascular obstruction (odds ratio, 0.37; 95% CI, 0.14-0.93 [P=0.035]). There was no significant difference in infarct size (P=0.491) and extent (P=0.753) or presence (P=0.914) of microvascular obstruction when comparing the morphine+metoclopramide group with the control group. Conclusions In this randomized study, intravenous administration of morphine before primary percutaneous coronary intervention resulted in a significant reduction of myocardial and microvascular damage following acute myocardial infarction. This effect was not observed in the morphine plus metoclopramide group. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02627950.

Keywords: infarct size; microvascular injury; morphine; myocardial infarction.

Conflict of interest statement

None.

Figures

Figure 1. Flow chart.
Figure 1. Flow chart.
CMR indicates cardiac magnetic resonance; MCP, Metoclopramide; NSTEMI, non–ST‐segment–elevation myocardial infarction; and STEMI, ST‐segment–elevation myocardial infarction.
Figure 2. Infarct size and microvascular obstruction…
Figure 2. Infarct size and microvascular obstruction (MVO).
Infarct size (A) and MVO (B) according to the randomized treatment groups. %LV indicates percentage of left ventricular mass.

References

    1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli‐Ducci C, Bueno H, Caforio AL, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST‐segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177. DOI: 10.1093/eurheartj/ehx393.
    1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315. DOI: 10.1093/eurheartj/ehv320.
    1. Nimmo WS, Wilson J, Prescott LF. Narcotic analgesics and delayed gastric emptying during labour. Lancet. 1975;1:890–893. DOI: 10.1016/S0140-6736(75)91687-6.
    1. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double‐blind, placebo‐controlled IMPRESSION trial. Eur Heart J. 2016;37:245–252. DOI: 10.1093/eurheartj/ehv547.
    1. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, Stavrou K, Migliorini A, Antoniucci D, Tamburino C, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST‐elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;8:e001593. DOI: 10.1161/CIRCINTERVENTIONS.114.001593.
    1. Silvain J, Storey RF, Cayla G, Esteve J‐B, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST‐segment elevation myocardial infarction. The PRIVATE‐ATLANTIC study. Thromb Haemost. 2016;116:369–378. DOI: 10.1160/TH15-12-0944.
    1. Sikora J, Niezgoda P, Barańska M, Buszko K, Skibińska N, Sroka W, Pstrągowski K, Siller‐Matula J, Bernd J, Gorog D, et al. METoclopramide Administration as a Strategy to Overcome MORPHine‐ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—the METAMORPHOSIS Trial. Thromb Haemost. 2018;118:2126–2133. DOI: 10.1055/s-0038-1675605.
    1. Saad M, Meyer‐Saraei R, de Waha‐Thiele S, Stiermaier T, Graf T, Fuernau G, Langer HF, Kurz T, Pöss J, Barkausen J, et al. Impact of morphine treatment with and without metoclopramide coadministration on ticagrelor induced platelet inhibition in acute myocardial infarction—the randomized MonAMI trial. Circulation. 2020;141:1354–1356. DOI: 10.1161/CIRCULATIONAHA.119.042816.
    1. Randhawa PK, Jaggi AS. Opioids in remote ischemic preconditioning‐induced cardioprotection. J Cardiovasc Pharmacol Ther. 2017;22:112–121. DOI: 10.1177/1074248416660621.
    1. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, Panagopoulou V, Tsarouchas K, Vavetsi S, Pyrgakis V, et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv. 2010;3:49–55. DOI: 10.1016/j.jcin.2009.10.015.
    1. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Urban D, Schuler G, Thiele H. Intravenous morphine administration and reperfusion success in ST‐elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol. 2015;104:727–734. DOI: 10.1007/s00392-015-0835-2.
    1. Bellandi B, Zocchi C, Xanthopoulou I, Scudiero F, Valenti R, Migliorini A, Antoniucci D, Marchionni N, Alexopoulos D, Parodi G. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol. 2016;221:567–571. DOI: 10.1016/j.ijcard.2016.06.204.
    1. Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, Elbaz M, Claeys MJ, Garcia‐Dorado D, Giraud C, et al. Effect and safety of morphine use in acute anterior ST‐segment elevation myocardial infarction. J Am Heart Assoc. 2018;7:e006833. DOI: 10.1161/JAHA.117.006833.
    1. Eitel I, Wang J, Stiermaier T, Fuernau G, Feistritzer HJ, Joost A, Jobs A, Meusel M, Blodau C, Desch S, et al. Impact of morphine treatment on infarct size and reperfusion injury in acute reperfused ST‐elevation myocardial infarction. J Clin Med. 2020;9:735. DOI: 10.3390/jcm9030735.
    1. Stiermaier T, Jobs A, de Waha S, Fuernau G, Poss J, Desch S, Thiele H, Eitel I. Optimized prognosis assessment in ST‐segment‐elevation myocardial infarction using a cardiac magnetic resonance imaging risk score. Circ Cardiovasc Imaging. 2017;10:e006774. DOI: 10.1161/CIRCIMAGING.117.006774.
    1. Steg PG, James SK, Atar D, Badano LP, Blomstrom‐Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez‐Aviles F, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. Eur Heart J. 2012;33:2569–2619. DOI: 10.1093/eurheartj/ehs215.
    1. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, Peacock WF, Pollack CV, Gibler WB, Peterson ED. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149:1043–1049. DOI: 10.1016/j.ahj.2005.02.010.
    1. Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, Cattan S, Steg G, Mock L, Ducrocq G, et al. Correlates of pre‐hospital morphine use in ST‐elevation myocardial infarction patients and its association with in‐hospital outcomes and long‐term mortality: the FAST‐MI (French Registry of Acute ST‐elevation and non‐ST‐elevation Myocardial Infarction) programme. Eur Heart J. 2016;37:1063–1071. DOI: 10.1093/eurheartj/ehv567.
    1. Furtado RH, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and cardiovascular outcomes among patients with non‐ST‐segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol. 2020;75:289–300. DOI: 10.1016/j.jacc.2019.11.035.
    1. Niccoli G, Montone RA, Ibanez B, Thiele H, Crea F, Heusch G, Bulluck H, Hausenloy DJ, Berry C, Stiermaier T, et al. Optimized treatment of ST‐elevation myocardial infarction. Circ Res. 2019;125:245–258. DOI: 10.1161/CIRCRESAHA.119.315344.
    1. Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A, Erbs S, Lurz P, Boudriot E, et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST‐elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur Heart J. 2015;36:3049–3057. DOI: 10.1093/eurheartj/ehv463.
    1. Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI‐2/ERIC‐PPCI): a single‐blind randomised controlled trial. Lancet. 2019;394:1415–1424. DOI: 10.1016/S0140-6736(19)32039-2.
    1. Stiermaier T, Jensen JO, Rommel KP, de Waha‐Thiele S, Fuernau G, Desch S, Thiele H, Eitel I. Combined intrahospital remote ischemic perconditioning and postconditioning improves clinical outcome in ST‐elevation myocardial infarction. Circ Res. 2019;124:1482–1491. DOI: 10.1161/CIRCRESAHA.118.314500.
    1. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol. 2002;34:1317–1323. DOI: 10.1006/jmcc.2002.2072.
    1. Takasaki Y, Wolff RA, Chien GL, van Winkle DM. Met5‐enkephalin protects isolated adult rabbit cardiomyocytes via delta‐opioid receptors. Am J Physiol. 1999;277:H2442–H2450. DOI: 10.1152/ajpheart.1999.277.6.H2442.
    1. Kamerman PR, Becker N, Fick LG. Interactions between metoclopramide and morphine: enhanced antinociception and motor dysfunction in rats. Clin Exp Pharmacol Physiol. 2007;34:106–112. DOI: 10.1111/j.1440-1681.2007.04533.x.
    1. Ung D, Cowan A, Parkman HP, Nagar S. Lack of interaction between metoclopramide and morphine in vitro and in mice. Xenobiotica. 2008;38:1365–1376. DOI: 10.1080/00498250802475285.
    1. Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli‐Ducci C, Croisille P, Dall'Armellina E, Dharmakumar R, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74:238–256. DOI: 10.1016/j.jacc.2019.05.024.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir